ABRILADA 40mg solution for injection

What is ABRILADA 40mg

ABRILADA 40mg is a biologic medication supplied as a solution for injection, provided in convenient pre-filled pens designed for subcutaneous administration. It contains the active ingredient adalimumab, a fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a key cytokine involved in inflammatory processes. ABRILADA is commonly used to treat various autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

• ABRILADA belongs to a class of drugs called TNF inhibitors that modulate the immune system to reduce excessive inflammation.
• It is indicated when conventional treatments have failed or are not tolerated, offering a targeted therapy approach.
• The pre-filled pens allow patients or caregivers to administer the medication at home after proper training, increasing treatment convenience and adherence.
• The included alcohol pads help maintain aseptic technique to minimize infection risk at the injection site.
• ABRILADA is a prescription-only medication and should be used under specialist supervision, such as by rheumatologists or gastroenterologists.

This medication plays an essential role in controlling chronic inflammatory diseases, improving quality of life by reducing symptoms and slowing disease progression.

How to use ABRILADA 40mg

Proper use of ABRILADA 40mg pre-filled pens is critical for safety and therapeutic success. Key instructions include:

• Administration Route: ABRILADA is given as a subcutaneous injection, typically in the thigh or abdomen. The upper arm may be used if someone else administers the injection.
• Preparation: Remove the pen from the refrigerator 15–30 minutes before injection to allow it to reach room temperature. Do not warm it in any other way.
• Injection Site: Clean the injection site with the provided alcohol pad to reduce infection risk.
• Using the Pen: Press the pre-filled pen firmly against the skin, activate it, and hold it in place for the recommended time (usually around 10 seconds) to ensure full dose delivery.
• Frequency: Dosing frequency depends on the condition but is commonly every other week; some conditions or patient responses may require weekly dosing.
• Missed Dose: Administer as soon as remembered unless the next dose is due soon. Do not double the dose.
• Disposal: Dispose of used pens safely in an approved sharps container.
• Training: Patients should receive proper training from healthcare providers before self-injection.

Following these guidelines helps ensure effective treatment with minimal discomfort or complications.

Mode of Action ABRILADA 40mg

ABRILADA’s active ingredient, adalimumab, works by specifically targeting and neutralizing tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in various autoimmune diseases. The detailed mode of action includes:

• TNF-α Binding: Adalimumab binds with high affinity to both soluble and membrane-bound TNF-α molecules, preventing them from interacting with TNF receptors on cell surfaces.
• Inhibition of Inflammatory Cascade: By blocking TNF-α, the drug suppresses downstream signaling pathways that lead to the release of other inflammatory mediators, chemokines, and adhesion molecules.
• Reduction of Immune Cell Activation: It decreases the activation and infiltration of inflammatory cells like macrophages and T-cells into affected tissues.
• Slowing Disease Progression: This immunomodulation results in reduced inflammation, tissue damage, and clinical symptoms in chronic autoimmune diseases.
• Long Half-Life: Adalimumab’s long half-life allows for sustained TNF-α suppression with dosing intervals of 1-2 weeks.

Overall, ABRILADA restores immune system balance by controlling excessive inflammation responsible for joint damage, skin lesions, and gastrointestinal symptoms in targeted diseases.

ABRILADA 40mg Interactions ABRILADA 40mg

Several drug interactions can influence ABRILADA’s effectiveness or increase adverse effects. Important considerations include:

• Other Immunosuppressants: Concomitant use with drugs like methotrexate, corticosteroids, or azathioprine may increase the risk of infections due to additive immunosuppression.
• Live Vaccines: Live or live-attenuated vaccines should be avoided during and shortly after treatment due to risk of vaccine-related infections.
• CYP450 Enzyme Modulators: Although adalimumab is a monoclonal antibody and not metabolized by cytochrome enzymes, TNF-α blockade can normalize CYP450 activity altered by inflammation, potentially affecting drugs metabolized by these enzymes (e.g., warfarin, cyclosporine).
• Other Biologics: Combining ABRILADA with other biologics (e.g., abatacept, rituximab) is generally not recommended due to increased infection risk.
• Antimalarials and Antibiotics: No significant direct interactions, but infection risks should be monitored.

Regular monitoring and communication with healthcare providers are essential to manage potential interactions safely.

Dosage of ABRILADA 40mg

The dosage of ABRILADA 40mg depends on the specific condition treated and patient factors. General dosing guidelines include:

• Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis: 40 mg administered every other week via subcutaneous injection. Some patients may require weekly dosing depending on clinical response.
• Plaque Psoriasis: Initial dose of 80 mg followed by 40 mg every other week starting one week after initial dose.
• Crohn’s Disease and Ulcerative Colitis: Induction dosing may start with higher or more frequent doses, then maintained at 40 mg every other week.
• Hidradenitis Suppurativa: Typically, 160 mg initially, followed by 80 mg at week 2, then 40 mg weekly or every other week as needed.
• Adjustments: Dosage may be adjusted based on efficacy, tolerability, or adverse effects, as well as in elderly or immunocompromised patients.
• Missed Dose: Administer as soon as possible unless the next scheduled dose is near; do not double doses.

Always follow the prescribing physician’s specific regimen tailored to individual patient needs.

Possible side effects of ABRILADA 40mg

ABRILADA, like other TNF inhibitors, may cause side effects. These range from mild to serious, and include:

• Common Side Effects: Injection site reactions (redness, swelling, pain), upper respiratory infections, headache, rash, nausea, and abdominal pain.
• Serious Infections: Increased risk of bacterial, viral, fungal, or opportunistic infections including tuberculosis (TB). Screening for latent TB is recommended before treatment.
• Allergic Reactions: Rare but possible anaphylaxis or severe hypersensitivity.
• Autoimmune Reactions: Rare cases of lupus-like syndrome, demyelinating disorders, or new onset/worsening heart failure.
• Malignancies: Slightly increased risk of lymphoma and other malignancies, though causality remains debated.
• Blood Disorders: Rare cytopenias such as neutropenia or thrombocytopenia.
• Neurologic Effects: Rare reports of seizures or multiple sclerosis-like symptoms.

Patients should report new symptoms promptly and attend regular follow-ups to monitor safety.

ABRILADA 40mg Contraindications ABRILADA 40mg

ABRILADA should not be used in the following situations:

• Known hypersensitivity to adalimumab or any component of the formulation.
• Active severe infections including sepsis, abscesses, or chronic infections.
• Untreated latent tuberculosis or active TB infection until adequately treated.
• Moderate to severe heart failure (NYHA class III/IV) due to risk of worsening symptoms.
• Use in patients with demyelinating diseases like multiple sclerosis unless benefits outweigh risks.
• Pregnancy and breastfeeding only if clearly needed and after careful risk-benefit analysis.

Comprehensive medical evaluation is required before starting ABRILADA.

Storage of ABRILADA 40mg

To maintain the integrity and effectiveness of ABRILADA 40mg pre-filled pens, proper storage is essential:

• Store refrigerated at 2°C to 8°C (36°F to 46°F).
• Protect from light by keeping the pens in the original